Dual Intron-Targeted CRISPR-Cas9-Mediated Disruption of the AML RUNX1-RUNX1T1 Fusion Gene Effectively Inhibits Proliferation and Decreases Tumor Volume In Vitro and In Vivo

Investigators presented a new dual intron-targeting CRISPR-Cas9 treatment strategy, for targeting t(8;21) found in 5–10% of de novo AML, which efficiently disrupted fusion genes without prior identification of breakpoint location.